{"disease":{"id":"recurrent-skin-cancer","name":"recurrent skin cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT02318771","title":"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT04315701","title":"A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01727076","title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02324608","title":"Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT02650635","title":"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}